Sale!

CBFB-MYH11Inv16 Qualitative Test Cost

Name: CBFB-MYH11Inv16 Qualitative Test Cost
SKU: TEST-5751
Price: 900 AED
Availability: InStock

Original price was: 1,200 د.إ.Current price is: 900 د.إ.

-25%

The CBFB-MYH11Inv16 Qualitative Test is a specialized diagnostic procedure aimed at detecting the presence of the CBFB-MYH11 fusion gene, which results from the inversion of chromosome 16 (inv(16)). This genetic anomaly is commonly associated with a subtype of acute myeloid leukemia (AML), known as AML M4Eo, and is crucial for the diagnosis, prognosis, and treatment planning of affected patients. The test involves analyzing the patient’s DNA to identify the specific genetic rearrangement, providing valuable insights into the genetic basis of the leukemia.

Performed at DNA Labs UAE, a leading facility in genetic testing, the test ensures high accuracy and reliability, employing state-of-the-art technology and methodologies. The cost of the CBFB-MYH11Inv16 Qualitative Test is set at 900 AED, reflecting the sophisticated nature of the analysis and the expertise required to interpret the results. This test is an essential tool in the personalized management of leukemia, enabling healthcare professionals to tailor treatments to the genetic profile of each patient, thereby optimizing outcomes.

Description

CBFB-MYH11Inv16 Qualitative Test

Test Name: CBFB-MYH11Inv16 Qualitative Test

Components: EDTA Vacutainer (2ml)

Price: 900.0 AED

Sample Condition: Bone marrow / Peripheral blood (Transport immediately)

Report Delivery: 3-4 days

Method: Real Time PCR

Test Type: Genetics

Doctor: General Physician

Test Department: DNA Labs UAE

Pre Test Information: CBFB-MYH11 Inv(16) Qualitative test can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

CBFB-MYH11[Inv(16)] is a qualitative genetic abnormality that is associated with certain types of leukemia, specifically acute myeloid leukemia (AML). It is a fusion gene resulting from an inversion of chromosome 16, which leads to the fusion of two genes: CBFB (core-binding factor subunit beta) and MYH11 (myosin heavy chain 11). This fusion gene disrupts normal cellular processes and promotes the development of leukemia. It is commonly found in a subtype of AML known as acute myelomonocytic leukemia (AML-M4) and is seen in both adults and children.

The presence of CBFB-MYH11[Inv(16)] is detected through genetic testing, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR). These tests help identify the abnormality and confirm the diagnosis of AML with inv(16). Qualitatively, the presence of CBFB-MYH11[Inv(16)] has prognostic significance. It is considered a favorable genetic abnormality in AML, as patients with this fusion gene tend to have a better response to treatment and a more favorable overall prognosis compared to other subtypes of AML.

However, it is important to note that individual prognosis can vary, and other factors such as age, overall health, and response to treatment also play a significant role in determining the outcome for patients with CBFB-MYH11[Inv(16)].

Overall, CBFB-MYH11[Inv(16)] is a qualitative genetic abnormality that is associated with a specific subtype of AML. Its presence has prognostic significance and helps guide treatment decisions and predict the overall outcome for patients with this type of leukemia.

Test Name	CBFB-MYH11Inv16 Qualitative Test
Components	EDTA Vacutainer (2ml)
Price	900.0 AED
Sample Condition	Bone marrow \/ Peripheral blood (Transport immediately)
Report Delivery	3-4 days
Method	Real Time PCR
Test type	Genetics
Doctor	General Physician
Test Department:
Pre Test Information	CBFB-MYH11 Inv(16)] Qualitative can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details	CBFB-MYH11[Inv(16)] is a qualitative genetic abnormality that is associated with certain types of leukemia, specifically acute myeloid leukemia (AML). It is a fusion gene resulting from an inversion of chromosome 16, which leads to the fusion of two genes: CBFB (core-binding factor subunit beta) and MYH11 (myosin heavy chain 11). This fusion gene disrupts normal cellular processes and promotes the development of leukemia. It is commonly found in a subtype of AML known as acute myelomonocytic leukemia (AML-M4) and is seen in both adults and children. The presence of CBFB-MYH11[Inv(16)] is detected through genetic testing, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR). These tests help identify the abnormality and confirm the diagnosis of AML with inv(16). Qualitatively, the presence of CBFB-MYH11[Inv(16)] has prognostic significance. It is considered a favorable genetic abnormality in AML, as patients with this fusion gene tend to have a better response to treatment and a more favorable overall prognosis compared to other subtypes of AML. However, it is important to note that individual prognosis can vary, and other factors such as age, overall health, and response to treatment also play a significant role in determining the outcome for patients with CBFB-MYH11[Inv(16)]. Overall, CBFB-MYH11[Inv(16)] is a qualitative genetic abnormality that is associated with a specific subtype of AML. Its presence has prognostic significance and helps guide treatment decisions and predict the overall outcome for patients with this type of leukemia.